Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
J Am Acad Dermatol 2024;90:1254–1256 doi 10.1016/j.jaad.2024.01.025
In this letter to the editor, Papp, et al. reported that brodalumab treatment in patients with psoriasis and an inadequate response to another biologic resulted in high rates of complete skin clearance with concurrent improvements in patient-reported outcomes after 26 weeks. The mean and median times to PASI 100 were 96.8 and 112 days, respectively.
Patients with moderate-to-severe PsO and inadequate response to another biologic after ≥12 weeks of stable-dose treatment were switched to brodalumab 210mg Q2W for 26 weeks as part of an open-label, Phase 4 study.
